LeMaitre Vascular
LMAT
212 hedge funds and large institutions have $1.27B invested in LeMaitre Vascular in 2023 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 61 increasing their positions, 79 reducing their positions, and 17 closing their positions.
165% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 17
31% more capital invested
Capital invested by funds: $968M → $1.27B (+$299M)
15% more funds holding
Funds holding: 184 → 212 (+28)
0.73% more ownership
Funds ownership: 85.08% → 85.81% (+0.73%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
23% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 79
43% less call options, than puts
Call options by funds: $27K | Put options by funds: $47K
Top Buyers
| 1 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
+$22M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$6.28M |
| 3 |
Millennium Management
New York
|
+$5.26M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$3.99M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$3.86M |
Top Sellers
LMAT Hedge Fund Activity: Q2 2023 in Review
212 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in LeMaitre Vascular (LMAT) for Q2 2023, worth a combined $1.27B — up 31% from $968M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new LMAT positions and 17 closed out — a net gain of 28 holders — while 61 added to existing stakes and 79 trimmed.
The largest buyer was Congress Asset Management, adding an estimated $22M. The largest seller was Cramer Rosenthal McGlynn, cutting an estimated $13.5M.
- 212 institutional investors held LeMaitre Vascular (LMAT) as of Q2 2023, up from 184 in Q1 2023.
- Funds reported $1.27B of LeMaitre Vascular stock for Q2 2023, up 31% quarter-over-quarter.
- 45 funds opened new LeMaitre Vascular positions in Q2 2023 and 17 closed out, a net change of +28 holders.
- The largest LeMaitre Vascular buyer in Q2 2023 was Congress Asset Management, an estimated $22M added.
- The largest LeMaitre Vascular seller in Q2 2023 was Cramer Rosenthal McGlynn, an estimated $13.5M sold.
Based on aggregated 13F filings for Q2 2023.